For the Inventor, By the Inventor

Enter assignee name

Carlsbad, CA, United States of America

Ionis Pharmaceuticals, Inc.

USPTO Granted Patents = 271

CIPO Patents = 11

EPO Patents = 133

Trademarks = 12

Forward Citations = 876

Loading Chart...

Loading Chart...

174 inventors (with patents filed for the assignee):

Susan M Freier (114 out of 254 patents)

Eric E Swayze (77 out of 201 patents)

Punit P Seth (56 out of 110 patents)

4. Frank Rigo (42 out of 50 patents)

5. Thazha P Prakash (40 out of 87 patents)

6. C Frank Bennett (32 out of 202 patents)

7. Huynh-Hoa Bui (21 out of 25 patents)

8. Mark J Graham (21 out of 66 patents)

9. Michael Oestergaard (18 out of 19 patents)

10. Stanley T Crooke (16 out of 76 patents)

11. Holly Kordasiewicz (15 out of 20 patents)

12. Rosanne M Crooke (15 out of 52 patents)

13. Gene Hung (13 out of 32 patents)

14. Sanjay Bhanot (12 out of 62 patents)

15. Shuling Guo (12 out of 13 patents)

Core Competencies:

Apolipoprotein Expression

HSD17B13 Modulators

Huntingtin Modulation

Antisense Oligonucleotides

SCN2A Modulation

Alpha Synuclein Expression

Dystrophia Myotonica-Protein Kinase

Complement Factor B Modulators

Fatty Liver Disease Treatment

Ataxin Expression Reduction

IRF4 Modulators

GLP-1 Receptor Ligands

271 patents: Sort by Forward Citations

1. 12502402 - Compounds and methods for modulating GFAP (2025-12-23),

2. 12410430 - Modulating apolipoprotein (A) expression (2025-09-09),

3. 12409188 - Modulators of HSD17B13 expression (2025-09-09),

4. 12384814 - Compounds and methods for reducing app expression (2025-08-12),

5. 12350285 - Compounds and methods for reducing ATXN3 expression (2025-07-08),

6. 12343357 - Compositions and methods for modulating MECP2 expression (2025-07-01),

7. 12297431 - Modulation of huntingtin expression (2025-05-13),

8. 12291709 - Compositions and methods for modulating apolipoprotein (a) expression (2025-05-06),

9. 12281305 - Compounds and methods for reducing prion expression (2025-04-21),

10. 12275940 - Conjugated antisense compounds and their use (2025-04-14),

11. 12241067 - Compounds and methods for reducing LRRK2 expression (2025-03-04),

12. 12234447 - Modified compounds and uses thereof (2025-02-25),

13. 12227746 - Compounds and methods for modulating SCN2A (2025-02-18),

14. 12215321 - Modulators of diacyglycerol acyltransferase 2 (DGAT2) (2025-02-04),

15. 12188020 - Methods for reducing Ataxin-2 expression (2025-01-07),

Ionis Pharmaceuticals, Inc. is a leading biotechnology company that specializes in the discovery and development of RNA-targeted therapeutics. With a focused approach on the treatment of serious and rare diseases, Ionis Pharmaceuticals utilizes its proprietary antisense technology platform to create breakthrough therapies. Their innovative drug discovery pipeline includes programs targeting various indications, including cardiovascular, neurological, and renal diseases.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

271 Patents

#13 in Carlsbad, CA

#338 in California

#1,531 in US

#3,132 in the World

Carlsbad, CA, United States of America

Ionis Pharmaceuticals, Inc.

Forward Citations = 876

174 inventors:

Susan M Freier (114 out of 254 patents)

Eric E Swayze (77 out of 201 patents)

Punit P Seth (56 out of 110 patents)

4. Frank Rigo (42 out of 50 patents)

5. Thazha P Prakash (40 out of 87 patents)

Please report any incorrect information to support@idiyas.com

Loading…